Zimislecel is an allogeneic stem cell-derived islet cell therapy that could eliminate the need for insulin in those who have type 1 diabetes. Regulatory submissions are expected in 2026, and if ...

Analysts are piling on the praise for Vertex Pharmaceuticals, reaffirming bullish ratings even as the stock slightly fumbles ...